Sino-Biocan's CELL-LAV achieves EU MDR certification

Sino-Biocan's CELL-LAV has obtained CE certification for MDR Class I medical devices, marking a milestone in meeting the European Medical Device Regulation (MDR) standards across technology, quality, and management systems.

2024-05-29

Sino-Biocan's Products: Inspiring Technological Innovation in NK Cell Therapy

Sino-Biocan's product line encompasses various stages of NK cell preparation, including cell isolation, cell culture, cell concentration, washing, and cell dispensing.

2024-05-17

Sino-Biocan has established a new factory in Jiaxing, Zhejiang, to produce consumables and liquid products of GMP grade

On April 27, 2024, Sino-Biocan (Jiaxing) Biomedical Devices Co., Ltd. held a groundbreaking ceremony at Xitang, Jiaxing, China, marking a significant milestone in the company's development.

2024-04-28

Sino-Biocan together with representatives from Chulalongkorn University of Thailand exemplifies their resolute determination in expanding into international markets

On April 25, 2024, Ms. Wei Dongbing, Chairwoman of Sino-Biocan Biotech Ltd., Professor Nattiya Hirankarn, Vice Dean of the Faculty of Medicine of Chulalongkorn University, Thailand, and Dr. Supannikar Tawinwung, Deputy Director of the Cell Immunology Research Laboratory, together visited the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences (IHCAMS) in collaboration with Juventas Cell Therapy Ltd., a subsidiary of He Yuan Bio-technology (Tianjin) Co., Ltd. They engaged in a cordial exchange and delved into the possibilities of future close collaborations.

2024-04-26

Sino-Biocan Completes Nearly Hundred Million RMB in Series B Financing to Provide High-Quality Fully Automatic Cell Preparation Systems for the Global Market

Sino-Biocan (Shanghai) Biotech Ltd. recently completed nearly a hundred million RMB in Series B financing. The raised funds will be primarily used to establish a modern production system, enhance overall research and development capabilities, and obtain global registration certification, aiming to rapidly expand into key global markets.

2024-03-27

Sino-Biocan has recently completed a Series A round of funding

Sino-Biocan(Beijing) Biotech Ltd(hereinafter referred to as “Sino-Biocan”) has recently completed a Series A round of funding of nearly RMB 100 million,led by Grand Flight Investment and continued by

2022-03-15

Sino-Biocan cell preparation tools production base inaugurated in Shanghai

Sino-Biocan cell preparation tools production base inaugurated in Shanghai

2021-11-18

Sino-Biocan has completed an angel round of funding in the tens of millions of dollars.

Sino-Biocan(Shanghai) Biotech Ltd has completed an angel round of funding in the tens of millions of dollars, with exclusive investment from Sinovation Ventures.

2021-10-06